A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

NCT03744676 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Disorder

Interventions

BIOLOGICAL: lisocabtagene maraleucel

Sponsor

Juno Therapeutics, a Subsidiary of Celgene

Collaborators

[object Object]